AVM Biotechnology, a clinical stage company, advancing AVM0703 for expeditious FDA approval in patients with relapsed/refractory "no-option" Non-Hodgkin’s Lymphoma/Leukemia. AVM0703 rapidly induces, expands, and mobilizes endogenous bispecific γδ TCR+ invariant TCR+ NKT-like cells by a glucocorticoid-receptor-independent mechanism and potentiates chemotherapy and CAR-T response in pre-clinical models. Durable clinical responses have been achieved with no DLT’s. Ph2/3 expected in NHL in 2022. Experienced leadership and innovation. Seeking strategic partner for commercial launch in 2023.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
Yes